###### Strengths and limitations of this study

-   A large cohort (1383 participants) was studied to explore the association between functional single nucleotide polymorphisms (SNPs) in *CD133* and overall survival (OS) of lung cancer patients.

-   Compared with *rs2240688* AA genotype, the variant AC/CC genotypes were independently associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype).

-   Higher hazard ratios for associations between *CD133 rs2240688* polymorphism and OS were observed in patients with adjuvant chemotherapy and radiotherapy for curative intent.

-   All participants were recruited from a single hospital, which may limit the generalisability of the study's results.

Introduction {#s1}
============

Lung cancer remains the most common cause of cancer-related deaths in China and worldwide.[@R1] The number of patients newly diagnosed with lung cancer was estimated at 1.8 million worldwide in 2012 and 500 000 in China. The number is expected to reach one million in China by 2025.[@R2] Approximately 83% of lung cancer patients have non-small cell lung cancer (NSCLC).[@R3] In addition, despite improvements in technologies and development of multiple treatments including surgery, radiotherapy, chemotherapy and utilisation of other biological agents, the prognosis of NSCLC is very poor due to recurrence and metastasis, with an overall 5-year survival rate \<16%.[@R4] Hence, it is necessary to identify biomarkers for the prevention, early diagnosis, monitoring of progression and therapeutic effects of NSCLC.

It is widely conceived that cancer stem cells (CSCs) are able to be self-renew and to produce heterogeneous lineages of cancer cells.[@R7] CSCs have been hypothesised as the origin of cancer due to their potent tumour-driving capability on tumour initiation, growth, metastasis and relapse.[@R9] The cell surface marker *CD133*, which is located in cellular protrusions, is related to tumorigenesis and cancer progression.[@R11] The *CD133* antigen, also known as prominin-1, has been used extensively as a biomarker of CSCs among different types of tumours, including colon cancer,[@R12] liver cancer,[@R13] gastric cancer,[@R14] brain tumour,[@R15] endometrial cancer[@R16] and ovarian cancer.[@R17]

The expression of *CD133* is significantly correlated with the development and prognosis of NSCLC.[@R18] As single nucleotide polymorphisms (SNPs) are considered to harbour information about genetic variation in functionality of the genome and susceptibility to tumour development,[@R19] we hypothesised that potential functional SNPs in *CD133* may influence the function of *CD133* and, consequentially, prognosis. A recent case--control study conducted by our team in a Chinese population showed that the *rs2240688* variant AC/CC genotypes were associated with a statistically increased risk of lung cancer.[@R19] However, another study found that *rs2240688C* variant genotypes were negatively associated with lung cancer and have a protective effect on overall survival (OS).[@R20] Considering the limited number of studies involving *CD133* genetic variants with NSCLC and their inconsistent results,[@R19] we investigated the associations between four functional SNPs in *CD133* and the prognosis of NSCLC in a Chinese population.

Methods {#s2}
=======

Study populations {#s2a}
-----------------

The sample in this retrospective cohort study included 1383 patients with histologically confirmed NSCLC, who were treated at the Department of General Surgery, Henan Provincial People's Hospital between January 2006 and December 2014. All participants with NSCLC in a case--control study which identified the relationship between polymorphisms of *CD133* and the risk of lung cancer were included in the previous retrospective cohort study.[@R19]

Eligibility for inclusion were the following criteria: (1) willing to participate in the study and sign an informed consent form; (2) aged ≥18 years with pathologically confirmed NSCLC; (3) had not received preoperative neoadjuvant therapies (including chemotherapy and radiotherapy); and (4) had a blood sample available for genotyping four selected SNPs in *CD133*. Those participants who were pregnant or breastfeeding, had previous cancer history, had other primary tumours, or had had primary tumours of the skin and nasopharynx, were excluded from this study. A personal identification number was assigned to every study subject at enrolment and specified on each case report form in order to maintain confidentiality.

The present study was performed in accordance with the Declaration of Helsinki, and the protocol and informed consent form have been reviewed and approved by the Institutional Review Boards of Henan Provincial People's Hospital. Written informed consent was provided by all the participants.

Initial screening, assessment and follow-up {#s2b}
-------------------------------------------

In this retrospective cohort study, blood samples and medical data were obtained from the biobank for lung cancer patients at the Department of General Surgery, Henan Provincial People's Hospital. This biobank consists of an electronic database of demographic and clinicopathological data (including age, sex, smoking status, histological tumour type, tumour-node-metastasis stage, chemotherapy or radiotherapy treatment), as well as blood samples. At the time of inclusion, written informed consent was obtained, and each participant was interviewed to obtain a detailed medical history. Blood samples were separated by centrifugation within 2 hours of collection. Serum samples were stored in aliquots below −70°C until analysis.

Details on surgical treatment were recorded including dates, types of surgeries, and complications. From the electronic database, we identified patients treated with adjuvant chemotherapy and we classified patients as being treated with adjuvant chemotherapy if the patient received platinum-based chemotherapy within 3 months of surgery. We classified patients as having received radiotherapy if they received external beam radiation, radioactive implants, radioisotopes, brachytherapy or other types of radiotherapy within 6 months of cancer diagnosis. We classified patients as having received curative intent radiotherapy if the patients with early disease (stages I and II) were treated with surgical resection in addition to radiotherapy. We classified patients as having received palliative radiotherapy if the patients with advanced or distant disease (stages III and IV) were treated with radiotherapy or in combination with other treatments for supportive care. Family history of cancer was defined as any types of cancer present in first degree relatives of the participants (parents, siblings and children).

OS was evaluated for all the patients with regular follow-up at 3-month intervals for the first 2 years after surgery, at 6-month intervals for years 3--5, and yearly thereafter according to the hospital guidelines. The patients who failed to attend follow-up visits were telephoned or their family members were contacted. Follow-up of patients for the present study was performed until July 2016.

SNP selection and genotyping {#s2c}
----------------------------

Potential SNPs should be common (≥5% minor allele frequency) in Chinese populations. Candidate *CD133* gene SNPs with potentially functional significance (that is, located in the promoter, the transcription factor-binding site, exon and 3'-untranslated region (UTR), or the coding regions with amino acid changes) were selected based on NCBI dbSNPs (<http://www.ncbi.nlm.nih.gov>) and SNPinfo Web Server (<http://www.snpinfo.niehs.nih.gov/snpfunc.htm>). As a result, four *CD133* candidate SNPs (*rs2240688* A\>C, *rs10022537* T\>A, *rs7686732* C\>G, *rs3130* C\>T) were identified and chosen in our model analysis. Three SNPs (*rs2240688*, *rs7686732*, *rs3130*) were located in the 3'-UTR of CD133, and *rs10022537* was located within the intron of the *CD133* gene.

Genomic DNA was extracted from the buffy coat fraction of each blood sample with a DNA blood Mini Kit (Qiagen Inc, Valencia, California, USA) according to the manufacturer's instructions. The genotyping methods of the four *CD133* SNPs are described in detail elsewhere.[@R19]

Statistical analysis {#s2d}
--------------------

We expect 3-year survival rates of 35% in patients with variant genotypes of *rs2240688* (AC/CC) and 27% in patients with *rs2240688* AA genotype. Based on a difference of 15% between groups on the primary outcome, assuming a 10% drop-out rate, a total of 1234 participants (at 1:1 ratio, 617 subjects in each group) are required to provide 80% power, with the use of a two-sided significance level of 0.05.

All statistical tests were performed using SAS 9.3 software (Cary, North Carolina, USA). Descriptive analysis results were presented as median and interquartile range (IQR) for continuous variables and frequencies (percentage) for categorical variables. Distributions of categorical variables, including demographic variables, prognosis factors and clinicopathological characteristics, were compared using the χ^2^ test/Fisher's exact test as appropriate. The primary endpoint was OS, which was calculated from the date of enrolment until the date of death or date of last follow-up. Survival curves of OS were estimated by the Kaplan-Meier method and compared by the log-rank test. The associations of *CD133* SNPs with OS were estimated by calculating hazard ratios (HR) and corresponding 95% confidence intervals (CI) from both univariate and multivariate Cox proportional hazards regression models, followed by stratification analysis by age, sex, smoking status, histopathology type, stage, family history, and application of chemotherapy and radiotherapy. In addition, the associations of *CD133* SNPs with OS were analysed under specific genetic models: genotypic, recessive and dominant models, but only the dominant model was used in the stratification analysis of *CD133 rs2240688* polymorphism as *rs2240688* (AC/CC) are variant genotypes. All these analyses were performed with or without adjustment for demographic variables and selected clinicopathological characteristics. All tests were two-sided and a value of p\<0.05 was considered to be statistically significant for all analyses.

Results {#s3}
=======

Baseline characteristics of the study population {#s3a}
------------------------------------------------

There were a total of 1383 participants with histologically confirmed NSCLC included in this retrospective cohort, including 793 (57.3%) lung adenocarcinomas, 331 (23.9%) lung squamous cell cancers, and 259 (18.7%) other types of NSCLC. [table 1](#T1){ref-type="table"} summarises the baseline characteristics of the study population by histopathology type. There were 726 (52.5%) males and 657 (47.5%) females, with ages ranging from 28 to 92 years (median 63 years; IQR 54--70 years). There were 394 (28.5%), 528 (38.2%) and 461 (33.3%) participants with stage I-II, III and IV NSCLC, respectively. There were a total of 842 (60.9%) participants who received surgical treatment, including 417 (30.2%) with lobectomy, 195 (14.1%) with segmentectomy and 230 (16.6%) with wedge resection. There were 607 (43.9%) participants who underwent adjuvant chemotherapy and 877 (63.4%) who underwent radiotherapy, including 622 (45.0%) for curative intent and 255 (18.4%) for palliative therapy.

###### 

Demographic and clinicopathological characteristics of non-small cell lung cancer patients recruited from Henan Provincial People's Hospital between January 2006 and December 2014

  Characteristics           Lung adenocarcinoma (n=793)   Lung squamous cell cancer (n=331)   Others (n=259)   Total (n=1383)
  ------------------------- ----------------------------- ----------------------------------- ---------------- ----------------
  Age (years)                                                                                                  
   \<65                     476 (60.0)                    151 (45.6)                          154 (59.5)       781 (56.5)
   ≥65                      317 (40.0)                    180 (54.4)                          105 (40.5)       602 (43.5)
  Sex                                                                                                          
   Male                     372 (46.9)                    206 (62.2)                          148 (57.1)       726 (52.5)
   Female                   421 (53.1)                    125 (37.8)                          111 (42.9)       657 (47.5)
  Smoking status                                                                                               
   Non-smoker               182 (23.0)                    24 (7.3)                            33 (12.7)        239 (17.3)
   Former smoker            322 (40.6)                    165 (49.8)                          100 (38.6)       587 (42.4)
   Current smoker           289 (36.4)                    142 (42.9)                          126 (48.6)       557 (40.3)
  Pack-years                                                                                                   
   ≤25                      158 (25.9)                    23 (7.5)                            28 (12.4)        209 (15.1)
   26--50                   233 (38.1)                    121 (39.4)                          96 (42.5)        450 (32.5)
   \>50                     220 (36.0)                    163 (53.1)                          102 (45.1)       485 (35.1)
  Stage                                                                                                        
   I-II                     234 (29.5)                    110 (33.2)                          50 (19.3)        394 (28.5)
   III                      271 (34.2)                    155 (46.8)                          102 (39.4)       528 (38.2)
   IV                       288 (36.3)                    66 (19.9)                           107 (41.3)       461 (33.3)
  Family history                                                                                               
   Yes                      121 (15.3)                    45 (13.6)                           39 (15.1)        205 (14.8)
   No                       672 (84.7)                    286 (86.4)                          220 (84.9)       1178 (85.2)
  Surgery                                                                                                      
   No                       274 (34.5)                    101 (30.5)                          166 (64.1)       541 (39.1)
   Lobectomy                271 (34.2)                    67 (20.2)                           79 (30.5)        417 (30.2)
   Segmentectomy            130 (16.4)                    62 (18.7)                           3 (1.2)          195 (14.1)
   Wedge resection          118 (14.9)                    101 (30.5)                          11 (4.3)         230 (16.6)
  History of radiotherapy                                                                                      
   No                       263 (33.2)                    100 (30.2)                          143 (55.2)       506 (36.6)
   Palliative therapy       116 (14.6)                    112 (33.8)                          27 (10.4)        255 (18.4)
   Curative intent          414 (52.2)                    119 (36.0)                          89 (34.4)        622 (45)
  Adjuvant chemotherapy                                                                                        
   No                       444 (56.0)                    177 (53.5)                          155 (59.9)       776 (56.1)
   Yes                      349 (44.0)                    154 (46.5)                          104 (40.1)       607 (43.9)

Association of *CD133* genotypes with OS {#s3b}
----------------------------------------

The enrolled NSCLC patients who returned for at least one follow-up visit had been followed for a median of 14.4 months (IQR 24.4 months). At the end of the study, 339 (24.5%) patients were alive and 1044 (75.5%) patients had died of any cause during follow-up.

The genotype distributions of the selected four SNPs in *CD133* and their associations with OS of NSCLC patients are shown in [table 2](#T2){ref-type="table"}. In all patients, variant genotypes of *rs2240688* (AC/CC) were statistically significantly associated with OS (log-rank p\<0.001 under a recessive model). Compared with *rs2240688* AA genotype, the variant AC/CC genotypes were associated with a statistically poorer OS of NSCLC (HR 1.29, 95% CI 1.13 to 1.47 for AC genotype; HR 2.22, 95% CI 1.84 to 2.68 for CC genotype). As shown in multivariate survival analysis using Cox proportional hazards regression, *rs2240688* variant genotypes remained significantly associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype) after adjustment for age, sex, smoking status, histopathology type, stage, chemotherapy and radiotherapy. However, the association between genotype distribution of the other three SNPs (*rs10022537* T\>A, *rs7686732* C\>G, *rs3130* C\>T) and OS of NSCLC patients was not observed.

###### 

Associations between *CD133* genotypes and overall survival among non-small cell lung cancer patients recruited from Henan Provincial People's Hospital between January 2006 and December 2014

  ------------------------------------------------------------------------------------------------------------------------
  Genotypes        No. of patients N (%)   No. of deaths N (%)   MST\       HR (95% CI)           Adjusted HR (95% CI)\*
                                                                 (months)                         
  ---------------- ----------------------- --------------------- ---------- --------------------- ------------------------
  *rs2240688*                                                                                     

   AA              652                     463 (71.0)            20.3       1.0                   1.0

   AC              555                     434 (78.2)            15.6       1.29 (1.13 to 1.47)   1.27 (1.12 to 1.45)

   CC              172                     143 (83.1)            8.2        2.22 (1.84 to 2.68)   2.32 (1.91 to 2.80)

  Recessive                                                                                       

   AA/AC           1207                    897 (74.3)            18.1       1.0                   1.0

   CC              172                     143 (83.1)            8.2        1.98 (1.66 to 2.36)   2.07 (1.73 to 2.48)

  Dominant                                                                                        

   AA              652                     463 (71.0)            20.3       1.0                   1.0

   AC/CC           727                     577 (79.4)            13.0       1.43 (1.27 to 1.62)   1.43 (1.26 to 1.61)

  *rs10022537*                                                                                    

   TT              913                     689 (75.5)            17.2       1.0                   1.0

   TA              413                     311 (75.3)            14.5       1.06 (0.93 to 1.22)   1.10 (0.96 to 1.27)

   AA              39                      30 (76.9)             15.2       1.14 (0.79 to 1.64)   1.00 (0.69 to 1.44)

  Dominant                                                                                        

   TT/TA           1326                    1000 (75.4)           16.8       1.0                   1.0

   AA              39                      30 (76.9)             15.2       1.12 (0.78 to 1.61)   0.96 (0.67 to 1.39)

  Recessive                                                                                       

   TT              913                     689 (75.5)            17.2       1.0                   1.0

   TA/AA           452                     341 (75.4)            14.5       1.07 (0.94 to 1.22)   1.13 (0.99 to 1.29)

  *rs7686732*^†^                                                                                  

   CC              398                     286 (71.9)            17.1       1.0                   1.0

   CG              88                      63 (71.6)             15.9       1.06 (0.80 to 1.39)   1.12 (0.85 to 1.49)

   GG              5                       4 (80.0)              20.1       1.33 (0.49 to 3.56)   1.26 (0.47 to 3.41)

  Dominant                                                                                        

   CC/CG           486                     349 (71.8)            17.0       1.0                   1.0

   GG              5                       4 (80.0)              20.1       1.31 (0.49 to 3.52)   1.24 (0.46 to 3.34)

  Recessive                                                                                       

   CC              398                     286 (71.9)            17.1       1.0                   1.0

   CG/GG           93                      67 (72.0)             15.9       1.07 (0.82 to 1.39)   1.13 (0.86 to 1.49)

  *rs3130*^†^                                                                                     

   CC              134                     92 (68.7)             18.0       1.0                   1.0

   CT              269                     201 (74.7)            17.0       1.13 (0.88 to 1.44)   1.14 (0.89 to 1.47)

   TT              92                      64 (69.6)             14.4       0.98 (0.72 to 1.36)   0.97 (0.70 to 1.34)

  Dominant                                                                                        

   CC/CT           403                     293 (72.7)            17.3       1.0                   1.0

   TT              92                      64 (69.6)             14.4       0.91 (0.69 to 1.19)   0.89 (0.68 to 1.18)

  Recessive                                                                                       

   CC              134                     92 (68.7)             18.0       1.0                   1.0

   CT/TT           361                     265 (73.4)            16.8       1.09 (0.86 to 1.38)   1.09 (0.86 to 1.39)
  ------------------------------------------------------------------------------------------------------------------------

\*Adjusted for age, sex, smoking status, histopathology type, stage, chemotherapy and radiotherapy.

†Genotyping of the two SNPs *rs7686732 and rs3130* was only carried out for a portion of the participants.

MST, median survival time; SNPs, single nucleotide polymorphisms.

[Figure 1](#F1){ref-type="fig"} shows the Kaplan-Meier curves for the OS among all NSCLC patients stratified by *rs2240688* genotypes. The median OS was 20.3 months (95% CI 18.7 to 22.7) for participants with *rs2240688* AA genotype, 15.6 months (95% CI 13.0 to 17.1) with *rs2240688* AC genotype, and 8.2 months (95% CI 7.1 to 9.9) with *rs2240688* CC genotype.

![Kaplan-Meier curves for overall survival among non-small cell lung cancer patients stratified by the *rs2240688* genotypes.](bmjopen-2017-016913f01){#F1}

***CD133*** genotypes and OS of NSCLC by clinicopathological characteristics {#s3c}
----------------------------------------------------------------------------

Stratified analysis was further performed for *rs2240688* A\>C by age, sex, smoking status, histopathology type, stage, family history of cancer, and application of chemotherapy and radiotherapy ([table 3](#T3){ref-type="table"}). Compared with the *rs2240688* AA genotype, the association between OS and *rs2240688* AC/CC variant genotypes also remained statistically significant in the subgroup of all ages, all sexes, former smoker, current smoker, lung adenocarcinoma, lung squamous cell cancer, other types of NSCLC, stage I-II, stage IV, with or without family history of cancer, without surgical treatment, with lobectomy, with wedge resection, with radiotherapy for curative intent, without radiotherapy, and with or without adjuvant chemotherapy. Higher HRs for associations between *CD133 rs2240688* polymorphism and OS were observed in patients with adjuvant chemotherapy (HR 1.86, 95% CI 1.52 to 2.26) and radiotherapy for curative intent (HR 1.90, 95% CI 1.55 to 2.33), compared with patients without adjuvant chemotherapy (HR 1.22, 95% CI 1.04 to 1.43) and those without radiotherapy (HR 1.24, 95% CI 1.02 to 1.51). Higher HRs for associations between *CD133 rs2240688* polymorphism and OS were also observed in patients with stage I-II and wedge resection surgery ([table 3](#T3){ref-type="table"}).

###### 

Stratified analysis for associations between *CD133 rs2240688* polymorphism (dominant for the C allele) and overal survival among non-small cell lung cancer patients recruited from Henan Provincial People's Hospital between January 2006 and December 2014

  ------------------------------------------------------------------------------------------------------------------------------------
  Variables                    *rs2240688* (death/patients)   MST\       HR (95% CI)    Adjusted HR (95% CI)\*   
                                                              (Months)                                           
  ---------------------------- ------------------------------ ---------- -------------- ------------------------ ---------------------
  Age (years)                                                                                                    

   \<65                        254/367                        324/411    20.1 vs 14.1   1.36 (1.16 to 1.61)      1.44 (1.22 to 1.70)

   ≥65                         209/285                        253/316    21.2 vs 11.9   1.54 (1.28 to 1.85)      1.46 (1.21 to 1.76)

  Sex                                                                                                            

   Male                        249/334                        326/390    18.1 vs 11.8   1.53 (1.30 to 1.80)      1.45 (1.23 to 1.71)

   Female                      214/318                        251/337    23.0 vs 16.8   1.32 (1.10 to 1.59)      1.45 (1.21 to 1.74)

  Smoking status                                                                                                 

   Non-smoker                  82/116                         89/120     18.3 vs 16.8   1.19 (0.88 to 1.60)      1.28 (0.94 to 1.74)

   Former smoker               188/278                        241/309    26.0 vs 13.4   1.54 (1.27 to 1.86)      1.52 (1.25 to 1.84)

   Current smoker              193/258                        247/298    19.0 vs 11.6   1.43 (1.18 to 1.72)      1.44 (1.19 to 1.74)

  Histopathology type                                                                                            

   Lung adenocarcinoma         253/377                        313/414    23.0 vs 16.0   1.40 (1.19 to 1.66)      1.44 (1.22 to 1.70)

   Lung squamous cell cancer   118/161                        132/170    21.0 vs 12.0   1.40 (1.09 to 1.79)      1.32 (1.03 to 1.71)

   Others                      92/114                         132/143    14.6 vs 9.0    1.54 (1.18 to 2.01)      1.51 (1.14 to 2.00)

  Stage                                                                                                          

   I-II                        78/169                         140/224    53.9 vs 18.0   2.09 (1.58 to 2.77)      2.28 (1.72 to 3.03)

   III                         217/272                        219/256    19.0 vs 15.5   1.15 (0.95 to 1.39)      1.17 (0.97 to 1.42)

   IV                          168/211                        218/247    13.4 vs 11.2   1.42 (1.16 to 1.73)      1.43 (1.16 to 1.75)

  Family history                                                                                                 

   Yes                         71/102                         80/103     22.2 vs 11.6   1.52 (1.10 to 2.09)      1.56 (1.12 to 2.17)

   No                          392/550                        497/624    20.0 vs 13.2   1.42 (1.24 to 1.62)      1.41 (1.23 to 1.61)

  Surgery                                                                                                        

   No                          191/232                        274/306    12.3 vs 9.6    1.36 (1.13 to 1.64)      1.38 (1.15 to 1.66)

   Lobectomy                   157/210                        179/206    26.0 vs 17.0   1.38 (1.11 to 1.71)      1.40 (1.12 to 1.74)

   Segmentectomy               61/95                          61/100     25.0 vs 21.6   1.14 (0.80 to 1.62)      1.27 (0.87 to 1.84)

   Wedge resection             54/115                         63/115     48.9 vs 23.4   1.72 (1.19 to 2.48)      1.75 (1.20 to 2.54)

  History of radiotherapy                                                                                        

   No                          196/237                        230/266    15.0 vs 12.0   1.17 (0.97 to 1.42)      1.24 (1.02 to 1.51)

   Palliative therapy          103/125                        113/130    19.0 vs 16.8   1.19 (0.91 to 1.56)      1.16 (0.88 to 1.53)

   Curative intent             164/290                        234/331    31.2 vs 12.8   1.90 (1.55 to 2.32)      1.90 (1.55 to 2.33)

  Adjuvant chemotherapy                                                                                          

   No                          294/384                        326/391    19.3 vs 16.2   1.23 (1.05 to 1.44)      1.22 (1.04 to 1.43)

   Yes                         169/268                        251/336    22.7 vs 9.9    1.78 (1.46 to 2.16)      1.86 (1.52 to 2.26)
  ------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for age, sex, smoking status, histopathology type, stage, chemotherapy and radiotherapy.

MST, median survival time.

Discussion {#s4}
==========

It is generally accepted that SNPs represent genetic variation in functionality of the genome and they are potential functional biomarkers for cancer aetiology. CSCs are responsible for tumour initiation, growth, migration, aggressiveness, metastasis, drug resistance and pluripotency.[@R8] In this study, information was collected to determine the role of CSCs in the clinical outcomes of NSCLC. We focused on the *CD133* gene that has been used to isolate CSCs. Four potential functional SNPs in the *CD133* gene locus were selected from SNP websites and peer-reviewed literature by using the candidate gene approach.

The prognostic and clinicopathological values of *CD133* protein and mRNA expression have been indicated in other studies.[@R3] In this hospital-based cohort study, we found that the variant genotypes (AC/CC) of *rs2240688* A\>C in the miRNA binding site of the stem cell marker gene *CD133* was associated with a significantly poorer prognosis for NSCLC patients. The association remained statistically significant (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype) after adjustment for age, sex, smoking status, histopathology type, stage, chemotherapy and radiotherapy. Additionally in the stratified analysis, the poorer prognosis associated with *rs2240688* A\>C variant genotypes did remain statistically significant in most subgroups. It was validated that *rs2240688* A-to-C transition gained a new binding site of the microRNA has-miR-135a/b, which may play a pivotal role in modulating the effect of the SNP on *CD133* expression.[@R20] The *rs2240688* A\>C variant genotypes are located in the 3'-UTR of *CD133*. SNPs in the 3'-UTR have been shown to have functional effects on the control of mRNA stability and efficiency through the regulation of miRNA, including miR-34a, −101,--128, −137 and −138.[@R22] It is inferred that SNPs in a target-binding site could alter the miRNA--mRNA interaction and thus affect the expression of miRNA targets. Considering the tumour-driving capability of CSCs on tumour growth and metastasis, the present study suggests that *CD133* might modify their metastasis competence of NSCLC by the miRNA binding site polymorphisms, which could be a putative target for improved therapies for treatment. Our subgroup analysis results showed that *rs2240688* A\>C variant genotypes had more effects on the prognosis of NSCLC among patients receiving adjuvant chemotherapy or radiotherapy. This may be due to its association with resistance to chemotherapy and radiotherapy.[@R23] Higher HRs for associations between CD133 rs2240688 polymorphism and OS were also observed in patients with stage I-II and wedge resection surgery. It may due to the effect of the *rs2240688* A\>C variant genotypes on tumour growth and metastasis which would result in greater impact among early stage patients.

However, the prognostic value of CSCs marker *CD133* in NSCLC remains controversial. Another study in China found that the *rs2240688* variant genotypes were associated with a favourable survival. Several studies found no significant association between the expression level of *CD133* and OS of NSCLC patients.[@R24] The inconsistent results may be explained in part by the different ethnic population, in addition to the different sampling methods used to select the populations under study. A meta-analysis showed that NSCLC patients with higher *CD133* expression had poor OS only in Asian patients, but not in Caucasian patients.[@R3] Therefore, high quality and interethnic studies with large samples should be undertaken to confirm the prognostic and clinical value of *CD133*.

This study had several limitations that should be taken into account. First, selection bias cannot be excluded even though inclusion/exclusion criteria were determined to minimise the bias. Potential confounding factors, such as clinicopathological characteristics, may be associated with SNPs in the *CD133* gene and also exert an effect on the overall mortality in our cohort of NSCLC patients. However, the independent association between SNPs in the *CD133* gene and OS of NSCLC patients was determined by using multivariate Cox proportional hazards regression models. Moreover, the HRs were largely very similar in all subgroups and similar to the overall HR, which implied no confounding by these factors. Second, in the hospital-based cohort study, all participants were recruited from a single hospital in Henan Province. Therefore, our study setting may limit the generalisability of our results. Finally, our study made many statistical comparisons, which might increase type I error.

Conclusions {#s5}
===========

This study confirmed a significant association between the SNP *rs2240688* A\>C of *CD133* and OS for NSCLC patients. Larger population-based studies in different ethnic groups are necessary to further validate the role and mechanisms of *CD133* in NSCLC.
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